4-氨基苄基磷酸二乙酯 | 20074-79-7

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氨基苄基磷酸二乙酯
• 中文别名: 4-氨基苯基磷酸二乙酯
• 英文名称: diethyl (4-aminobenzyl)phosphonate
• 英文别名: diethyl p-aminobenzylphosphonate；p-aminobenzylphosphonic acid diethyl ester；diethyl (4-aminophenyl)methylphosphonate；Diethyl 4-aminobenzylphosphonate；4-(diethoxyphosphorylmethyl)aniline
• CAS: 20074-79-7
• 化学式: C₁₁H₁₈NO₃P
• mdl: MFCD00007913
• 分子量: 243.243
• InChiKey: ZVAYUUUQOCPZCZ-UHFFFAOYSA-N

物化性质

• 熔点：
  90-94 °C(lit.)
• 沸点：
  383.3±25.0 °C(Predicted)
• 密度：
  1.153±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解。避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 安全说明：
  S22,S24/25
• WGK Germany：
  3
• 海关编码：
  2931900090
• RTECS号：
  SZ6480000
• 储存条件：
  在密封的贮藏器内，并将其存放在阴凉、干燥的地方。

SDS

Name:	Diethyl p-aminobenzylphosphonate Material Safety Data Sheet
Synonym:	p-aminobenzylphosphoric acid diethyl ester
CAS:	20074-79-7

Section 1 - Chemical Product MSDS Name:Diethyl p-aminobenzylphosphonate Material Safety Data Sheet
Synonym:p-aminobenzylphosphoric acid diethyl ester

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
20074-79-7	Diethyl p-aminobenzylphosphonate	100.0	243-504-8

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid immediately.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Antidote: None reported.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 20074-79-7: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: beige
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 91.00 - 94.00 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: N/A
Explosion Limits, upper: N/A
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H18NO3P
Molecular Weight: 243.24

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, strong oxidants.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Phosphine, carbon monoxide, oxides of phosphorus, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 20074-79-7: SZ6480000 LD50/LC50:
Not available.
Carcinogenicity:
Diethyl p-aminobenzylphosphonate - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION
Other No information available.

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 20074-79-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 20074-79-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 20074-79-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用

4-氨基苄基磷酸二乙酯是一种用于有机合成和医药研发的中间体，在实验室有机合成及化工医药合成过程中广泛应用。

反应信息

• 作为反应物：
  描述：

  4-氨基苄基磷酸二乙酯 生成 {4-[bis-(2-iodo-ethyl)-amino]-benzyl}-phosphonic acid diethyl ester
  参考文献：
  名称：

  Nitrogen Mustard Derivatives Containing the Phosphonate Group¹

  摘要：

  DOI：

  10.1021/ja01521a029
• 作为产物：
  描述：

  1-(氯甲基)-4-硝基苯 在 palladium on activated charcoal 、 氢气 作用下， 以 乙醇 为溶剂， 反应 18.0h， 生成 4-氨基苄基磷酸二乙酯
  参考文献：
  名称：

  7H-吡咯并[2,3-d]吡啶衍生物作为有效的FAK抑制剂的发现：设计，合成，生物学评估和分子对接研究。

  摘要：

  黏着斑激酶（FAK）是负责各种肿瘤类型发展的细胞内非受体酪氨酸激酶。为了探索新的有效抑制剂，在基于结构的设计策略的基础上，设计并合成了两个系列的2,4-二取代-7 H-吡咯并[2,3- d ]嘧啶衍生物。生物学评估表明，这些新化合物中的大多数可以有效抑制FAK激酶，从而导致有希望的抑制剂对抗U-87MG，A-549和MDA-MB-231癌细胞的增殖。其中，优化的化合物18h 在U-87MG，A-549和MDA-MB-231细胞中均有效抑制酶（IC 50 = 19.1 nM），并显示出比TAE-226更强的效力，IC 50分别为0.35、0.24和0.34μM。化合物18h是多靶激酶抑制剂。此外，化合物18h 对正常人细胞株HK2的细胞毒性也较小（IC 50 = 3.72μM）。根据流式细胞术和伤口愈合试验结果，化合物18h有效诱导MDA-MB-231细胞凋亡和G0 / G1期阻滞，并抑制U

  DOI：

  10.1016/j.bioorg.2020.104092
• 作为试剂：
  描述：

  、 4-氨基苄基磷酸二乙酯 在 4-氨基苄基磷酸二乙酯 作用下， 以44的产率得到(2R,4S)-(-)-N-[4-(二乙氧基磷基甲基)苯基]-4-甲基-7,8-(甲二氧基)-5-羰基-1,2,4,5-四氢-3-苯并噻庚英-2-甲酰胺
  参考文献：
  名称：

  J. Med. Chem. 1999, 42, 751-760

  摘要：

  DOI：

文献信息

• [EN] AGENT FOR PREVENTING OR TREATING NEUROPATHY<br/>[FR] AGENT POUR LA PRÉVENTION OU LE TRAITEMENT DE NEUROPATHIE
  申请人：TAKEDA CHEMICAL INDUSTRIES LTD

  公开号：WO2004039365A1

  公开（公告）日：2004-05-13

  The present invention provides an agent for preventing or treating neuropathy having superior action and low toxicity. This agent comprises a compound represented by the formula:wherein ring A is a 5-membered aromatic heterocycle containing 2 or more nitrogen atoms, which may further have substituent(s);B is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group;X is a divalent acyclic hydrocarbon group;Z is -O-, -S-, -NR2-, -CONR2- or -NR2CO- (R2 is a hydrogen atom or an optionally substituted alkyl group);Y is a bond or a divalent acyclic hydrocarbon group;R1 is an optionally substituted cyclic group, an optionally substituted amino group or an optionally substituted acyl group, provided that when the 5-membered aromatic heterocycle represented by ring A is imidazole, then Z should not be -O-, or a salt thereof.

  本发明提供了一种具有优越作用和低毒性的预防或治疗神经病的药剂。该药剂包括一个由以下式表示的化合物：其中环A是含有2个或更多氮原子的5元芳香杂环，可能进一步具有取代基；B是一个可选择取代的碳氢基团或可选择取代的杂环基团；X是二价的无环碳氢基团；Z是-O-，-S-，-NR2-，-CONR2-或-NR2CO-（R2是氢原子或可选择取代的烷基基团）；Y是键或二价的无环碳氢基团；R1是可选择取代的环基团，可选择取代的氨基团或可选择取代的酰基团，但当环A表示的5元芳香杂环是咪唑时，Z不应为-O-，或其盐。
• Anti-Viral Compounds
  申请人：DeGoey David A.

  公开号：US20100317568A1

  公开（公告）日：2010-12-16

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

  描述了一种有效抑制丙型肝炎病毒（“HCV”）复制的化合物。本发明还涉及制备这种化合物的方法、包含这种化合物的组合物，以及使用这种化合物治疗HCV感染的方法。
• [EN] IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES<br/>[FR] IMIDAZOPYRROLOPYRIDINE EN TANT QU'INHIBITEURS DE LA FAMILLE JAK DE KINASES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2018112382A1

  公开（公告）日：2018-06-21

  2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.

  2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile化合物，含有它们的药物组合物，制备它们的方法，以及使用它们的方法，包括用于治疗由JAK介导的疾病状态、紊乱和疾病，如炎症性肠病的方法。
• Second-generation aryl isonitrile compounds targeting multidrug-resistant Staphylococcus aureus
  作者：Kwaku Kyei-Baffour、Haroon Mohammad、Mohamed N. Seleem、Mingji Dai

  DOI：10.1016/j.bmc.2019.03.034

  日期：2019.5

  4 µM) and were safe to human keratinocytes. Compound 19, with an additional isonitrile group exhibited improved activity against MRSA compared to the first-generation lead compound. This compound emerged as a candidate worthy of further investigation and further reinforced the importance of the isonitrile functionality in the compounds' anti-MRSA activity. In a murine skin wound model, 19 significantly

  抗生素耐药性仍然是全球主要的公共卫生威胁，需要不断发现具有未开发脚手架的新型抗菌剂。我们合成的第一代芳基异腈化合物的结构活性关系导致了一个最初的先导分子，该分子指导了第二代芳基异腈的合成。在这个由20种化合物组成的新系列中，三种类似物可抑制耐甲氧西林的金黄色葡萄球菌（MRSA）（从1至4 µM）的生长，并且对人角质形成细胞安全。与第一代先导化合物相比，具有额外的异腈基的化合物19表现出对MRSA改善的活性。该化合物成为值得进一步研究的候选化合物，并进一步增强了异腈功能在该化合物的抗MRSA活性中的重要性。在鼠类皮肤伤口模型中，19与抗生素夫西地酸相似，可显着降低MRSA的负担。总之，已鉴定出19种化合物对MRSA有效。
• Pyrazole compounds
  申请人：——

  公开号：US20030060453A1

  公开（公告）日：2003-03-27

  Pharmaceutical compositions and compounds are provided. The compounds of the invention demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, pharmaceutical compositions of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical compositions are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are substituted pyrazoles and pyrazolines.

  提供药物组合物和化合物。发明的化合物显示出抗增殖活性，并且可能促进缺乏正常细胞周期和死亡调控的细胞的凋亡。发明的一个实施例提供了化合物与生理可接受载体组合的药物组合物。该药物组合物可用于治疗过度增殖障碍，包括肿瘤生长、淋巴增殖性疾病、血管生成。发明的化合物是取代吡唑和吡唑啉。

表征谱图